Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Changes Name Prepares for Public Offering

Premium

P

RINCETON, NJ--Orchid Biocomputer said it has changed its name to Orchid BioSciences to reflect the company’s current and future direction in the genetic diversity and pharmacogenetics fields. "Orchid has grown in new directions that didn’t exist when the company formed in 1995," said Dale Pfost, Orchid’s chairman, president, and CEO. "We believe our new name is commensurate with the future of Orchid and the many exciting possibilities that await the company, the genetics industry, and the future of medicine and bioscience."

According to a report in Nature Biotechnology, Pfost said the company is planning an initial public offering in coming weeks to capitalize on the favorable biotech markets.

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.